Ventus Therapeutics' VENT-03 Demonstrates Promising Phase 1 Results as First-in-Class cGAS Inhibitor
核心洞察
Ventus Therapeutics (搜索) announced positive Phase 1 clinical trial results for VENT-03, a first-in-class oral cGAS (搜索) inhibitor, showing it was safe and well-tolerated in healthy volunteers.
The trial demonstrated a favorable pharmacokinetic profile, supporting once-daily dosing and achieving full target inhibition, paving the way for further development.
Ventus plans to initiate a Phase 2 trial in 2025 to evaluate VENT-03 in patients with systemic lupus erythematosus (搜索) (SLE (搜索)), targeting a key driver of inflammation.
Ventus Therapeutics (搜索) has announced the successful completion of its Phase 1 clinical trial for VENT-03, a novel, orally administered cyclic GMP-AMP synthase (cGAS (搜索)) inhibitor. The trial, which involved 72 healthy adult volunteers, demonstrated that VENT-03 was safe and well-tolerated across a range of doses, with a pharmacokinetic profile suitable for once-daily dosing. These findings position VENT-03 as a potential first-in-class treatment for autoimmune and inflammatory diseases.
The Phase 1 trial assessed the pharmacokinetics, target engagement, safety, and tolerability of VENT-03. According to the company, no dose-limiting or dose-related toxicities, serious adverse events, or clinically significant changes in laboratory parameters, ECG, or vital signs were observed. All treatment-related adverse events were mild and transient.
Favorable Pharmacokinetics and Target Inhibition
VENT-03 exhibited a pharmacokinetic profile that supports convenient once-daily oral administration. Furthermore, the drug achieved plasma concentrations necessary for complete cGAS (搜索) target inhibition, demonstrating robust pharmacodynamic activity. Ventus Therapeutics (搜索) plans to present detailed data from the Phase 1 trial at an upcoming medical conference.
Targeting Lupus with cGAS Inhibition
Systemic lupus erythematosus (搜索) (SLE (搜索)) is a chronic autoimmune disease affecting millions worldwide. Current treatments, often injectable biologics targeting the type I interferon or BAFF pathways, address only certain aspects of the disease. Ventus Therapeutics (搜索) is gearing up to initiate a Phase 2 trial with VENT-03 in SLE patients in 2025.
Xavier Valencia, M.D., Head of Clinical Development at Ventus, stated that a once-daily oral cGAS (搜索) inhibitor has the potential to modulate both the type I interferon and BAFF pathways, impacting multiple facets of SLE (搜索) and potentially providing superior efficacy compared to existing treatments. The cGAS pathway is activated by the presence of double-stranded DNA (dsDNA) in the cytoplasm, often resulting from cellular dysfunction, which is a hallmark of autoimmune and inflammatory diseases. Activation of cGAS leads to cGAMP formation, activation of STING, pronounced inflammation, and tissue damage.
Ventus' ReSOLVE™ Platform
Ventus Therapeutics (搜索) utilizes its proprietary ReSOLVE™ platform to discover and develop differentiated small-molecule therapeutics. This platform combines AI/ML, structural biology, and biophysics to model protein dynamics, facilitating the development of high-quality small molecules for historically challenging targets. Marcelo Bigal, M.D., Ph.D., President and CEO of Ventus, emphasized that the profile demonstrated by VENT-03 qualifies it as a potential best-in-class anti-cGAS (搜索) medication, underscoring the power of their ReSOLVE™ platform.